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Abstract
Background: Cyclophosphamide, an alkylating agent, has been used as an immunosuppressant in
the treatment of various autoimmune disorders and malignancies. It is highly capable of reducing T
and B lymphocytes.
Case presentation: Regular blood tests are important to detect bone marrow suppression. The
risk of opportunistic infection such as pneumonia secondary to pneumocystic carinii increases
drastically with lymphopaenia. Hence, prophylactic co-trimoxazole is frequently prescribed as long
as patients are on cyclophosphamide.
Conclusion:  The benefits and toxicity risks of intravenous versus oral administration of
cyclophosphamide are described in this article.
Case presentation
A 60-year-old lady presented with 3 months history of
non-specific flu-like symptoms, fever, lethargy and pol-
yarthralgia. Urinalysis revealed haematoproteinuria. She
was admitted with acute renal failure and found to have a
C-ANCA (anti-neutrophil cytoplasmic antibodies) associ-
ated vasculitis with high PR3 (proteinase 3). Serum creat-
inine was >900 umol/L. Renal biopsy revealed multiple
cellular creascents. Treatment with Intravenous(IV)
monthly pulsed cyclophosphamide(CYC), steroid and
plasma exchange(PE) were carried out. Although she had
a prolonged hospital admission, she eventually became
dialysis independent. Her serum creatinine was 195
umol/L at 3 months after her initial treatment.
Discussion
Wegener's granulomatosis (WEG) is a type of serious vas-
culitis. Without treatment, mortality is as high as 90% at
2 years. Presenting features include corneal ulceration,
episcleritis, abnormalities in the respiratory tract, propto-
sis, diplopia, mononeuritis multiplex, pulmonary haem-
orrhage and renal failure. Rhinorrhoea, bloody nasal
discharge, oral ulcers, myalgia and polyarthralgia
appeared to be the most common presenting complaints.
Cyclophosphamide with glucocorticoid has been fre-
quently used in managing various types of vasculitis
including WEG. It is an alkylating agent which impairs
DNA replication leading to cell death. It also has the abil-
ity to inhibit T cell proliferation. There are serious adverse
effects associated with this agent including premature
ovarian failure, bone marrow suppression, bladder cancer
and hyponatraemia due to SIADH (syndrome of inappro-
priate antidiuretic hormone secretion).
There has been much interest in the route of administra-
tion of CYC in vasculitic disorders. The higher the cumu-
lative dose, the higher the risk of toxicity is. Some studies
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have reported the risk of infection and lymphopaenia are
lower with IV pulsed CYC as the total accumulative dose
is much lower [1]. Bladder toxicity also appears to be sig-
nificantly lower in patients who receive CYC through the
IV route. The incident of bladder cancer is around 15% at
15 years [2]. The benefit of MESNA (sodium 2-mercap-
toethanesulfonate) to reduce haemorrhagic cystitis and
bladder cancer is not supported by all studies. Permanent
and premature ovarian failure is a well recognised compli-
cation of CYC. The risk of gonadal failure increases with
age. One study has shown the risk of ovarian dysfunction
is 10% and 60% in women who are younger than 26 years
old and those older than 30 years old respectively [3].
Males who receive this agent are also at risk of infertility.
Although more challenging in women, gonadal cryop-
reservation can be performed in both genders. Gonado-
tropin-releasing hormone agonist has been shown to be
useful to reduce the risk of premature ovarian failure.
Conclusion
Cyclophosphamide can be a very useful drug given in the
right setting with sufficient monitoring. There is increas-
ing evidence to support IV CYC therapy is equally as effec-
tive as oral therapy and is associated with less toxicity in
patients with systemic vasculitis.
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